Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medpace (MEDP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Medpace (MEDP) Upgraded to Strong Buy: Here's What You Should Know

Since its IPO five years ago, this clinical trial specialist is up over 700%.

This Diversified Healthcare Stock Offers Explosive Biotech-Like Growth

Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q3 2021 Results - Earnings Call Transcript

Medpace (MEDP) delivered earnings and revenue surprises of 20.56% and 1.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Tops Q3 Earnings and Revenue Estimates

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Financial Results Revenue for the three months ended September 30, 2021 increased 28.3% to $295.6 million, compared to $230.4 million for the comparable prior-year period. On a constant currency organic basis, revenue for the third quarter of 2021 increased 28.1% compared to the third quarter of 2020. Backlog as of Se

Medpace Holdings, Inc. Reports Third Quarter 2021 Results

Medpace Hldgs (NASDAQ:MEDP) is set to give its latest quarterly earnings report on Monday, 2021-10-25. Here's what investors need to know before the announcement.

Earnings Outlook For Medpace Hldgs

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Medpace (MEDP) Q3 Earnings Expected to Decline

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2021 financial results after the market close on Monday, October 25, 2021. The Company will host a conference call the following morning, Tuesday, October 26, 2021, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 5177474. To access the conference call v

Medpace Holdings, Inc. to Report Third Quarter 2021 Financial Results on October 25, 2021

Medpace (MEDP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Medpace (MEDP) Moves 3.3% Higher: Will This Strength Last?

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will present at the following investor conference: Baird's Global Healthcare Conference Date: Tuesday, September 14, 2021 Presentation: 8:30 a.m. ET Speakers: Jesse Geiger, President, and Kevin Brady, Chief Financial Officer A live webcast of the presentation will be accessible through the “Investors” section of the Company's website at www.medpace.com and will be available for replay followin

Medpace Holdings, Inc. to Present at Baird's Global Healthcare Conference

Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Medpace (MEDP) Moves to Buy: Rationale Behind the Upgrade

Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q2 2021 Results - Earnings Call Transcript

Medpace (MEDP) delivered earnings and revenue surprises of 8.16% and 2.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Q2 Earnings and Revenues Beat Estimates

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Financial Results Revenue for the three months ended June 30, 2021 increased 35.8% to $278.3 million, compared to $205.0 million for the comparable prior-year period. On a constant currency organic basis, revenue for the second quarter of 2021 increased 34.4% compared to the second quarter of 2020. Backlog as of June 30,

Medpace Holdings, Inc. Reports Second Quarter 2021 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger

Medpace Holdings, Inc. Announces Senior Leadership Changes

Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Medpace Holdings is a healthcare diagnostics and research firm based in Cincinnati, Ohio.

Medpace Holdings: The Pullback Is An Opportunity, As It Keeps Chugging Higher

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2021 financial results after the market close on Monday, July 26, 2021. The Company will host a conference call the following morning, Tuesday, July 27, 2021, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 4092073. To access the conference call via we

Medpace Holdings, Inc. to Report Second Quarter 2021 Financial Results on July 26, 2021

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will present at the following investor conference: Jefferies Virtual Healthcare Conference Date: Wednesday, June 2, 2021 Presentation: 9:00 a.m. ET Speakers: August Troendle, President & Chief Executive Officer, Jesse Geiger, Chief Financial Officer & Chief Operating Officer, Laboratory Operations, and Kevin Brady, Executive Director of Finance A live webcast of the presentation will b

Medpace Holdings, Inc. to Present at the Jefferies Virtual Healthcare Conference

Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q1 2021 Results - Earnings Call Transcript

Medpace (MEDP) delivered earnings and revenue surprises of 15.84% and -1.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Q1 Earnings Surpass Estimates

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2021. First Quarter 2021 Financial Results Revenue for the three months ended March 31, 2021 increased 12.6% to $260.0 million, compared to $230.9 million for the comparable prior-year period. On a constant currency organic basis, revenue for the first quarter of 2021 increased 11.6% compared to the first quarter of 2020. Backlog as of March 31,

Medpace Holdings, Inc. Reports First Quarter 2021 Results

Align Technology

Charles River Laboratories

Medical stocks Medpace Holdings and Charles River Laboratories were making inroads toward profit-taking zones on Friday as Align Technology flirted with a breakout out of a cup base. The post Three Scorching Medical Stocks To Watch, Including One Near A Buy Point appeared first on Investor's Business Daily.

Three Scorching Medical Stocks To Watch, Including One Near A Buy Point

Medpace is in a potential buy range with its next earnings report scheduled for Apr. 26. The medical stock is about 3% above a 177.22 buy point from a second-stage.

Medpace Holdings Stock At The Top Of Buy Range With Earnings On Deck

Medpace is near a buy zone with earnings due on or around Apr. 26. The post Top-Rated Medpace Near Buy Zone With Earnings Due appeared first on Investor's Business Daily.

News for Medpace Holdings Stock (MEDP)